he amyloid hypothesis of Alzheimer's disease: past and present, hopes and disappointments ; Амилоидная гипотеза болезни Альцгеймера: прошлое и настоящее, надежды и разочарования

Συγγραφείς: I. V. Litvinenko, A. Yu. Emelin, V. Yu. Lobzin, K. A. Kolmakova, K. M. Naumov, I. A. Lupanov, G. A. Kilivaeva, M. R. Alizade, И. В. Литвиненко, А. Ю. Емелин, В. Ю. Лобзин, К. А. Колмакова, К. М. Наумов, И. А. Лупанов, Г. А. Киливаева, М. Р. Ализаде

Συνεισφορές: Публикация статьи поддержана ООО «Мерц Фарма».

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 11, No 3 (2019); 4-10 ; Неврология, нейропсихиатрия, психосоматика; Vol 11, No 3 (2019); 4-10 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2019-3

Θεματικοί όροι: моноклональные антитела, amyloid hypothesis, amyloid plaques, treatment of Alzheimer's disease, tau protein, secretase, monoclonal antibodies, амилоидная гипотеза, амилоидные бляшки, лечение болезни Альцгеймера, тау-протеин, секретазы

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1166/921; Беляков СА. О патологоанатомических изменениях центральной нервной системы при старческом слабоумии. Дис. докт. мед. наук. Санкт-Петербург; 1887. 72 с.; Одинак ММ, Литвиненко ИВ, Емелин АЮ и др. Патоморфологические изменения при деменции: приоритет отечественных исследователей. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(6):28-34.; Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und phychishGerichtliche Medizin. 1907;64:146-8.; Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984 May 16;120(3):885-90.; Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science. 1992 Apr 10;256(5054):184-5.; Huber G, Bailly Y, Martin JR, et al. Synaptic betaamyloid precursor proteins increase with learning capacity in rats. Neuroscience. 1997 Sep;80(2):313-20.; Nalivaeva NN, Turner AJ. The amyloid precursor protein: A biochemical enigma in brain development, function and disease. FEBS Lett. 2013 Jun 27;587(13):2046-54. doi:10.1016/j.febslet.2013.05.010. Epub 2013 May 16.; Goozee K, Chatterjee P, James I, et al. Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load. Mol Psychiatry. 2018 Aug;23(8):1807-1812. doi:10.1038/mp.2017.146. Epub 2017 Jul 11.; Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis. 2009;16(4):879-95. doi:10.3233/JAD-2009-1010.; Ayton S, Fazlollahi A, Bourgeat P. Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline. Brain. 2017 Aug 1;140(8):2112-2119. doi:10.1093/brain/awx137.; Guillemot J, Canuel R, Essalmani, et al. Implication of the proprotein convertases in iron homeostasis: proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin. Hepatology. 2013 Jun;57(6):2514-24. doi:10.1002/hep.26297. Epub 2013 May 15.; Ayton S, Faux NG, Bush AI. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat Commun. 2015 May 19;6:6760. doi:10.1038/ncomms7760.; Diouf I, Fazlollahi A, Bush AI, Ayton S. Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying βamyloid pathology. Alzheimer's disease Neuroimaging Initiative. Neurobiol Dis. 2019 Apr;124:335-339. doi:10.1016/j.nbd.2018.12. 010. Epub 2018 Dec 14.; Cline EN, Bicca MA, Viola KL, Klein WL. The amyloid-oligomer hypothesis: Beginning of the third decade. J Alzheimers Dis. 2018;64(s1): S567-S610. doi:10.3233/JAD-179941.; Kuruva CS, Reddy PH. Amyloid beta modulators and neuroprotection in Alzheimer's disease: A critical appraisal. Drug Discov Today. 2017 Feb;22(2):223-233. doi:10.1016/j.drudis.2016.10.010. Epub 2016 Oct 27.; Емелин А.Ю, Лобзин ВЮ, Воробьёв СВ. Когнитивные нарушения: руководство для врачей. Москва; 2019. 416 с.; Hellstrom-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with A beta levels. Neurobiol Aging. 2008 Feb;29(2):210-21. Epub 2006 Nov 13.; Hanger DP, Anderton BH, Noble W. Tau phosphorilation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009 Mar;15(3):112-9. doi:10.1016/j.molmed.2009. 01.003. Epub 2009 Feb 24.; Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59.; De Lacoste M, White CL3rd. The role of cortical connectivity in Alzheimer's disease pathogenesis: a review and model system. Neurobiol Aging. 1993 Jan-Feb;14(1):1-16.; Boncristiano S, Calhoun ME, Howard V, et al. Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol Aging. 2005 May;26(5):607-13.; Spires TL, Meyer-Luehmann M, Stern EA, et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005 Aug 3;25(31): 7278-87.; Kukar T, Prescott S, Eriksen JL, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007 Jul 24;8:54.; Li-Blatter X, Beck A, Seelig A. P-glycoprotein-ATPase modulation: the molecular mechanisms. Biophys J. 2012 Mar 21;102(6):1383-93. doi:10.1016/j.bpj.2012.02.018. Epub 2012 Mar 20.; Xia X, Qian S, Soriano S, et al. Loss of presenilin 1 is associated with enhanced betacatenin signaling and skin tumorigenesis. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10863-8. Epub 2001 Aug 21.; Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. doi:10.1056/NEJMoa1210951.; Haapasalo A, Kovacs DM. The many substrates of presenilin/_-secretase. J Alzheimers Dis. 2011;25(1):3-28. doi:10.3233/JAD-2011-101065.; Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-tomoderateAlzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):322-33. doi:10.1056/NEJMoa1304839.; Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21. doi:10.1056/NEJMoa 1312889.; Morris GP, Clark IA, Vissel B. Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease. Acta Neuropathol Commun. 2014 Sep 18;2:135. doi:10.1186/s40478-014-0135-5.; Kametani F, Hasegawa M. Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease. Front Neurosci. 2018 Jan 30;12:25. doi:10.3389/fnins.2018.00025. eCollection 2018.; Armstrong RA, Nochlin D, Sumi M, Alvord EC. Neuropathological changes in the visual cortex in Alzheimer's disease. Neurosci Res Commun. 1990;6(3):163-71.; Paroni G, Bisceglia P, Seripa D. Understanding the Amyloid Hypothesis in Alzheimer's Disease. J Alzheimers Dis. 2019;68(2):493-510. doi:10.3233/JAD-180802.; Lacor PN, Buniel MC, Furlow PW, et al. Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease. J Neurosci. 2007 Jan 24; 27(4):796-807.; Carroll BJ. Ageing, stress and the brain. Endocrine Facets of Ageing. Novartis Foundation Symposium 2002;242:26-36.; Armstrong RA. A critical analysis of the 'amyloid cascade hypothesis'. Folia Neuropathol 2014;52(3):211-225.; Литвиненко ИВ, Емелин АЮ, Лобзин ВЮ, Колмакова КА. Нейровизуализационные методы диагностики болезни Альцгеймера и цереброваскулярных заболеваний, сопровождающихся когнитивными нарушениями. Неврология, нейропсихиатрия, психосоматика. 2019;11(3S):18-25. doi:10.14412/2074-2711-2019-3S-18-25; Huang YM, Shen J, Zhao HL. Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease. J Am Geriatr Soc. 2019 Apr; 67(4):841-844.; Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015 Apr 10;10(4):e0123289.; Schmidt R, Ropele S, Pendl B, et al. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. Folia Neuropathol. 2014;52(3): 211-25. doi:10.1136/jnnp.2007.141648.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1166
https://doi.org/10.14412/2074-2711-2019-3-4-10

How to effectively treat migraine attacks

Συγγραφείς: V. A. Parfyonov

Πηγή: Медицинский совет, Vol 0, Iss 18, Pp 20-26 (2014)

Θεματικοί όροι: профилактика болезни альцгеймера, лечение болезни альцгеймера, ингибиторы центральной ацетилхолинэстеразы, мемантина гидрохлорид, холина аль-фосцерат, исследование ascomalva, migraine, pain medications, triptans, acetylsalicylic acid, paracetamol, caffeine, excedrin, Medicine

Περιγραφή αρχείου: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/794; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Σύνδεσμος πρόσβασης: https://doaj.org/article/d0a8705275364c68b4bd5db2beb0770b